Lansforsakringar Fondforvaltning’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$10M Sell
46,265
-1,542
-3% -$295K 0.04% 300
2026
Q1
$8.76M Sell
47,807
-918
-2% -$169K 0.05% 303
2025
Q4
$8.58M Buy
48,725
+417
+0.9% +$68.1K 0.04% 312
2025
Q3
$6.77M Buy
48,308
+561
+1% +$75.8K 0.04% 344
2025
Q2
$6M Sell
47,747
-385
-0.8% -$48K 0.03% 362
2025
Q1
$6.59M Sell
48,132
-130
-0.3% -$18.6K 0.04% 341
2024
Q4
$7.38M Buy
+48,262
New +$8.14M 0.04% 331

Other funds holding BIIB

Lansforsakringar Fondforvaltning's BIIB Position: Q2 2026 in Review

Lansforsakringar Fondforvaltning reduced its Biogen (BIIB) stake by 3.2% in Q2 2026, selling an estimated $295K and leaving 46,265 shares worth $10M. The position accounts for 0.04% of the portfolio, ranked #300.

Lansforsakringar Fondforvaltning first reported a position in BIIB in Q4 2024 and has held it in 7 quarters since. 1,046 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Lansforsakringar Fondforvaltning held 46,265 shares of Biogen worth $10M as of Q2 2026.
  • Lansforsakringar Fondforvaltning sold 1,542 Biogen shares in Q2 2026, an estimated $295K.
  • Biogen made up 0.04% of Lansforsakringar Fondforvaltning's portfolio in Q2 2026, its #300 holding.
  • Lansforsakringar Fondforvaltning first reported a position in Biogen in Q4 2024 and has held it in 7 quarters since.
  • 1,046 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Lansforsakringar Fondforvaltning's 13F filing for Q2 2026, filed 13 Aug 2026.